NuCana plc
NCNA evidence brief
What we can confirm
- Market Cap:
- $5.5M
What it means
What to watch
Prepared research question
What matters most for NCNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NCNA
NuCana plc is a clinical-stage biopharmaceutical company applying its proprietary ProTide technology to develop novel nucleoside analog-based cancer therapies, with lead candidates NUC-7738 and NUC-3373 in early-to-mid-stage clinical trials.
Key risk: No approved products
Market Cap
$5.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 4 clinical trials for NuCana plc.
NuCana plc is a clinical-stage biopharmaceutical company applying its proprietary ProTide technology to develop novel nucleoside analog-based cancer therapies, with lead candidates NUC-7738 and NUC-3373 in early-to-mid-stage clinical trials.
- Clinical-stage biopharmaceutical company focused on improving chemotherapy outcomes via ProTide technology [sec · filed 2026-03-19].
- Lead candidates: NUC-7738 (Phase 1/2 monotherapy and combination with pembrolizumab) and NUC-3373 (Phase 1b/2 modular trial) [sec · filed 2026-03-19].
- No approved products; no product revenues generated to date [sec · filed 2026-03-19].
- Cash and cash equivalents of £24.3 million as of December 31, 2025 [sec · filed 2026-03-19].
- Accumulated deficit of £252.3 million and net cash used in operating activities of £7.5 million for the year ended December 31, 2025 [sec · filed 2026-03-19].
What works
- ProTide technology platform is proprietary and aims to improve existing nucleoside analog chemotherapies, potentially offering a differentiated approach [sec · filed 2026-03-19].
- Company holds worldwide rights to all product candidates under development, allowing broad commercial flexibility [sec · filed 2026-03-19].
- Lead programs are advancing into later-stage trials (Phase 2 for NUC-7738, modular Phase 1b/2 for NUC-3373), indicating some clinical progress [sec · filed 2026-03-19].
What to weigh
- No products have gained marketing approval; revenue generation is years away, if ever [sec · filed 2026-03-19].
- Accumulated deficit of £252.3 million and cash burn of £7.5 million in 2025; cash runway limited to £24.3 million as of year-end 2025 [sec · filed 2026-03-19].
- Early-stage clinical programs carry high risk of failure; the company acknowledges that drug development risk is high [sec · filed 2026-03-19].
- Substantial additional funding is required and may not be available on acceptable terms, threatening continued operations [sec · filed 2026-03-19].
From the filings
Quoted directly from source documents.
Company is clinical-stage and uses ProTide technology to improve nucleoside analog chemotherapies.
“We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide ™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines”
SEC filings · March 19, 2026
No approved products and no product revenues.
“We currently do not have any products that have gained marketing approval.”
SEC filings · March 19, 2026
Cash and cash equivalents of £24.3 million as of December 31, 2025.
“We had cash and cash equivalents of £24.3 million at December 31, 2025.”
SEC filings · March 19, 2026
Accumulated deficit of £252.3 million.
“have an accumulated deficit totaling £252.3 million”
SEC filings · March 19, 2026
Risks & what to watch (4)›
Key risks
- No approved products — Company has no marketed products; revenue generation is years away, if ever [sec · filed 2026-03-19].
- Limited cash runway — Cash of £24.3M as of Dec 2025; operating cash burn of £7.5M in 2025; additional funding needed [sec · filed 2026-03-19].
- High clinical failure risk — Early-stage programs (Phase 1/2) have inherently high risk of failure; company acknowledges this [sec · filed 2026-03-19].
- Dependence on future financing — Substantial additional funding required; may not be available on acceptable terms or at all [sec · filed 2026-03-19].
What to watch
- Progress of NUC-7738 Phase 2 combination trial with pembrolizumab in melanoma [sec · filed 2026-03-19].
- Selection of optimal combinations and indications for NUC-3373 after Phase 1b/2 modular trial [sec · filed 2026-03-19].
- Ability to secure additional financing given cash runway of £24.3M as of Dec 2025 [sec · filed 2026-03-19].
- Any updates on potential partnerships or commercialization strategy for U.S. and Europe [sec · filed 2026-03-19].
Sources: SEC filings · Generated October 1, 2026 · How we verify sources →
Run NuCana plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NuCana plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$61K
| Holder | Shares | Value |
|---|---|---|
| glass jacobson investment advisors llc | 15,000 | $21K |
| citadel advisors llc | 13,855 | $20K |
| jane street group, llc | 10,511 | $15K |
| rhumbline advisers | 3,722 | $5K |
| virtu financial llc | 13,433 | $19 |
| caitong international asset management co., ltd | 2 | $3 |
| morgan stanley | 2 | $3 |
| acadian asset management llc | 2 | $0 |
Short Interest
as of May 1, 2026- % of float
- 4.1%
- Days to cover
- 3.3
- Shares short
- 169,130
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NCNA short interestFrequently asked questions
What is the AI investment thesis for NuCana plc?
NuCana plc is a clinical-stage biopharmaceutical company applying its proprietary ProTide technology to develop novel nucleoside analog-based cancer therapies, with lead candidates NUC-7738 and NUC-3373 in early-to-mid-stage clinical trials.
Who is the CEO of NuCana plc?
Mr. Hugh Stephen Griffith is the chief executive officer of NuCana plc (NCNA).
Where is NuCana plc headquartered?
NuCana plc (NCNA) is headquartered in Edinburgh, United Kingdom.
What therapeutic areas does NuCana plc focus on?
NuCana plc develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.